Newbury Pharmaceuticals

Newbury Pharmaceuticals is a Swedish pharmaceutical company focused on in-licensed prescription drugs, specialty medicines, and own-brand products. The company works through partnerships to register, commercialize, and distribute pharmaceuticals across the Nordic markets, while also serving selected international customers through indirect channels.

— Newbury Pharmaceuticals
%
In-licensed prescription drugs45% Prescription medicines acquired through licensing agreements and commercialized in Newbury's markets.
Specialty drugs25% Specialty pharmaceutical products targeted at specific therapeutic or market niches.
Own brands15% Products marketed under Newbury's own brand names, built around licensed product rights.
Distribution and commercialization services15% Commercial and distribution activities for partners not directly represented in the Nordics.

Newbury sells to pharmaceutical buyers in the Nordic region and to international customers reached through indirect...

  • Nordic pharmacies and healthcare channelsprimary

    Buy prescription and specialty medicines for patient use in the Nordic market.

  • Pharmaceutical partnersprimary

    License product rights to Newbury and use it to register and commercialize products in Scandinavia.

  • International distributors and customerssecondary

    Purchase through indirect channels outside the Nordics where Newbury extends partner products.

  • Patients and end-market stakeholderssecondary

    Indirect beneficiaries of specialty drugs and own-brand medicines commercialized by Newbury.

Newbury is anchored in the Nordic markets, where it focuses on building direct business and market expertise...

  • •Nordic markets are the core commercial focus
  • •Scandinavia is central to registration and commercialization work
  • •International sales are handled through indirect channels outside the Nordics
  • •Middle East activity is exposed to freight and logistics disruption
  • •Geographic reach matters because market access is country-specific in pharma

Newbury's strategy is to build a portfolio of licensed pharmaceutical products through partnerships rather than...

01
Grow the licensed product portfoliomedium-term

A broader portfolio increases commercial reach without requiring internal R&D.

02
Deepen Nordic market presenceshort-term

Local registration and commercialization expertise is the core competitive advantage.

03
Extend reach beyond the Nordicsmedium-term

International channels diversify the customer base and broaden product monetization.

Newbury's business depends on third-party product rights, partner relationships, and access to regulated pharmaceutical...

high

Dependence on third-party product rights

The company does not develop its own drugs and must secure licensed products from partners.

Scope
Portfolio availability and commercial continuity
Materiality
high
high

Regulatory and registration risk

Pharmaceutical commercialization depends on approvals, registrations, and local compliance.

Scope
Nordic and international market access
Materiality
high
high

Customer credit and collection risk

The company disclosed delayed payments from international sales customers.

Scope
Receivables and cash conversion
Materiality
high
medium

Geopolitical and logistics disruption in the Middle East

The company disclosed slower business activity and higher freight/logistics costs in the region.

Scope
International operations in the Middle East
Materiality
medium
medium

Trade policy and tariff changes

Cross-border pharmaceutical distribution can be affected by new barriers or duties.

Scope
International sourcing and sales
Materiality
medium
Revenue recognition on pharmaceutical sales and distribution
Affects quarterly revenue comparability
Trade receivables and expected credit losses
Can affect reported assets and earnings
Related-party and partner receivables
May influence asset carrying values
Investment in subsidiary shares and impairment
Can materially affect parent-company equity and profit
Employee stock option accounting
Affects operating costs and share count

CUMBERLAND PHARMACEUTICALS INC

CPIX · Pharmaceutical Preparations

Skye Bioscience, Inc.

SKYE · Pharmaceutical Preparations

NovoCure Ltd

NVCR · Surgical & Medical Instruments & Apparatus

ACADIA PHARMACEUTICALS INC

ACAD · Pharmaceutical Preparations

Corbus Pharmaceuticals Holdings, Inc.

CRBP · Pharmaceutical Preparations

NewAmsterdam Pharma Co N.V.

NAMS · Pharmaceutical Preparations

: 11/08/2026